Multifunctional Hyaluronic Acid and Chondroitin Sulfate Nanoparticles: Impact of Glycosaminoglycan Presentation on Receptor Mediated Cellular Uptake and Immune Activation
Source abstract
Abstract
Hyaluronic acid (HA) and chondroitin sulfate (CS) polymers are extensively used for various biomedical applications, such as for tissue engineering, drug delivery, and gene delivery. Although both these biopolymers are known to target cell surface CD44 receptors, their relative cellular targeting properties and immune activation potential have never been evaluated. In this article, we present the synthesis and characterization of novel self-assembled supramolecular HA and CS nanoparticles (NPs). These NPs were developed using fluorescein as a hydrophobic component that induced amphiphilicity in biopolymers and also efficiently stabilized anticancer drug doxorubicin (DOX) promoting a near zero-order drug release. The cellular uptake and cytotoxicity studies of these NPs in different human cancer lines, namely, human colorectal carcinoma cell line HCT116 and human breast cancer cell line MCF-7 demonstrated dose dependent cytotoxicity. Interestingly, both NPs showed CD44 dependent cellular uptake with the CS-DOX NP displaying higher dose-dependent cytotoxicity than the HA-DOX NP in different mammalian cells tested. Immunological evaluation of these nanocarriers in an ex vivo human whole blood model revealed that unlike unmodified polymers, the HA NP and CS NP surprisingly showed platelet aggregation and thrombin-antithrombin complex formation at high concentrations (0.8 mg/mL). We also observed a clear difference in early- and late-stage complement activation (C3a and sC5b-9) with CS and CS NP triggering significant complement activation at high concentrations (0.08-0.8 mg/mL), unlike HA and HA NP. These results offer new insight into designing glycosaminoglycan-based NPs and understanding their hematological responses and targeting ability.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Proteoglycans and glycosaminoglycans research · Dendrimers and Hyperbranched Polymers · Glycosylation and Glycoproteins Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Ångström Laboratory, Science for Life Laboratory, Uppsala University, S-75121 Uppsala, Sweden
BioMediTech - Institute of Biosciences and Medical Technology, Bioengineering and Nanomedicine Group, Tampere University of Technology, 33520 Tampere, Finland
Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, S-75121 Uppsala, Sweden
Funding
Seventh Framework Programme · Konungariket Sveriges Regering
References (46)
Show source-provided references
1. 10.1016/j.cca.2014.05.00410.1016/j.cca.2014.05.004 ↗
2. 10.1016/j.jconrel.2015.06.00110.1016/j.jconrel.2015.06.001 ↗
3. 10.1016/j.jconrel.2014.03.05110.1016/j.jconrel.2014.03.051 ↗
4. 10.1517/17425247.2012.72096910.1517/17425247.2012.720969 ↗
5. 10.1021/nn101990a10.1021/nn101990a ↗
6. 10.1016/j.jconrel.2010.04.00310.1016/j.jconrel.2010.04.003 ↗
7. 10.1111/j.1742-4658.2012.08529.x10.1111/j.1742-4658.2012.08529.x ↗
8. 10.1016/S1357-2725(01)00166-210.1016/S1357-2725(01)00166-2 ↗
9. 10.1002/adfm.20150069510.1002/adfm.201500695 ↗
10. 10.1039/C5CC09215A10.1039/C5CC09215A ↗
11. 10.1039/C6BM00335D10.1039/C6BM00335D ↗
12. 10.1021/ja902857b10.1021/ja902857b ↗
13. 10.1002/mabi.20130038310.1002/mabi.201300383 ↗
14. Goebeler M. · J. Cell Sci. · 1996 · 109 · 195710.1242/jcs.109.7.1957 ↗
15. 10.1517/14728222.11.8.110310.1517/14728222.11.8.1103 ↗
16. 10.1021/nn202070n10.1021/nn202070n ↗
17. 10.3390/biom204054910.3390/biom2040549 ↗
18. 10.1111/j.1440-1681.1984.tb00235.x10.1111/j.1440-1681.1984.tb00235.x ↗
19. 10.1006/abio.2001.554510.1006/abio.2001.5545 ↗
20. 10.1016/j.jconrel.2009.09.01010.1016/j.jconrel.2009.09.010 ↗
21. 10.1016/j.actbio.2009.12.04910.1016/j.actbio.2009.12.049 ↗
22. 10.1016/j.carbpol.2011.10.05010.1016/j.carbpol.2011.10.050 ↗
23. 10.1016/j.copbio.2016.02.00810.1016/j.copbio.2016.02.008 ↗
24. 10.1016/j.actbio.2012.06.04310.1016/j.actbio.2012.06.043 ↗
25. 10.1021/bm200083n10.1021/bm200083n ↗
26. 10.1016/j.biomaterials.2011.10.06410.1016/j.biomaterials.2011.10.064 ↗
27. 10.1002/mabi.20110035210.1002/mabi.201100352 ↗
28. 10.1016/j.ijpharm.2010.04.04110.1016/j.ijpharm.2010.04.041 ↗
29. 10.1021/bc100411910.1021/bc1004119 ↗
30. 10.1155/2010/90693610.1155/2010/906936 ↗
31. 10.1021/bm900116r10.1021/bm900116r ↗
32. 10.1038/nrd108810.1038/nrd1088 ↗
33. 10.1016/j.biomaterials.2009.12.04310.1016/j.biomaterials.2009.12.043 ↗
34. Ekdahl K. N. · 2013 · 25710.1007/978-1-4614-4118-2_18 ↗
35. Karjalainen K. · Acta. Ophthalmol. Suppl. · 1971 · 109 · 1
36. 10.1021/bm400612h10.1021/bm400612h ↗
37. 10.1006/bioo.1997.106310.1006/bioo.1997.1063 ↗
38. 10.1016/j.jconrel.2004.06.00310.1016/j.jconrel.2004.06.003 ↗
39. 10.1021/ma001839210.1021/ma0018392 ↗
40. 10.1002/anie.20150918210.1002/anie.201509182 ↗
41. 10.1073/pnas.95.20.1156110.1073/pnas.95.20.11561 ↗
42. 10.1021/mp400607h10.1021/mp400607h ↗
43. 10.1016/j.jconrel.2011.06.03110.1016/j.jconrel.2011.06.031 ↗
44. Greene R. F. · Cancer Res. · 1983 · 43 · 3417
45. 10.1002/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO;2-M10.1002/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO;2-M ↗
46. 10.7326/0003-4819-80-2-24910.7326/0003-4819-80-2-249 ↗